Aurinia Pharmaceuticals Inc. | Mutual Funds
Mutual Funds that own Aurinia Pharmaceuticals Inc.
Polar Capital Funds Plc - Healthcare Opportunities Fund
2,653,347
3.38%
53,147
0.85%
07/31/2018
Biotech Growth Trust Plc (The)
1,797,426
2.29%
2,502
1.44%
09/30/2017
FTIF SICAV - Franklin Biotechnology Discovery Fund
1,088,900
1.39%
0
0.26%
06/30/2018
iShares Nasdaq Biotechnology ETF
970,951
1.24%
-12,705
0.06%
09/06/2018
Franklin Biotechnology Discovery Fund
575,500
0.73%
0
0.22%
03/31/2018
Candriam Equities L - Biotechnology
157,500
0.2%
39,500
0.07%
07/31/2018
119,910
0.15%
0
0.45%
05/31/2018
AST FI Pyramis Quantitative Portfolio
108,600
0.14%
0
0.01%
03/29/2018
iShares S&P/TSX Small Cap Index ETF
70,424
0.09%
0
0.42%
09/06/2018
68,700
0.09%
-27,700
0.19%
01/31/2018
| Address |
4464 Markham Street
Victoria British Columbia V8Z 7X8
Canada
|
|
Employees
|
- |
| Website |
http://www.auriniapharma.com |
| Updated |
07/08/2019 |
| Aurinia Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada. . |
